Skip to main content

Anticancer Activity of the Ascidian Polyclinum Indicum against Cervical Cancer Cells (HeLa) Mediated through Apoptosis Induction

Buy Article:

$68.00 + tax (Refund Policy)

The cytotoxicity-based chemotherapy treatment for cancer has significant side effects. Therefore, anticancer research is concentrated on identifying an effective drug with minimal side effects. The methanol extract of ascidian Polyclinum indicum and its column fraction PI-8 showed cytotoxicity against cervical cancer cells (HeLa) with an IC50 of 77.5 μg/mL and 1.12 μg/mL. Hoechst staining with PI-8 treated cells portrayed the apoptotic events in drug-induced apoptosis. The PI-8 markedly arrested G2/M and S phases in cell cycle. The occurrence of a second population of apoptotic cells in the range of lower Forward Scatter (FSC) and higher Side Scatter (SSC) compared to control cells indicated the characteristic feature of the cells dying of apoptosis. DNA fragmentation has established the apoptotic event. The study emphasized the fraction PI-8 of P. indicum as a potential lead compound for apoptosis targeted anticancer drugs. The molecular mechanism and chemotherapeutic potential of the fraction PI-8 need further investigation.





Keywords: AIDS; Anticancer activity; Aplidium albicans; Ciona edwardsii; Ciona intestinalis; Column Fractionation; DNA Fragmentation Assay; Dendrodoa grossularia; ELISA; Ecteinascidia turbinata; FACSCalibur; Flow Cytometry; Halocynthia roretzi; HeLa cells; Hoechst Staining; Lissoclinum patella; MTT Assay; Pseudomonas fluorescens; Streptomycin; Thin Layer Chromatography; Trabectedin; Trididemnum solidum; Yondelis; apoptosis; ascidian; column fraction PI-8; cytotoxicity; flash column chromatography; flow cytometry; fucoxanthinol; halocynthiaxanthin; hoechst staining; polyclinum indicum

Document Type: Research Article

Publication date: 01 November 2010

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content